Furthermore, the intratumoral treatment of doxorubicin at a low dose (2.5 mg/kg of body weight) along with either the potent EGFR inhibitor/compound 1e or standard EGFR inhibitor, PD153035 in mice xenotransplanted with CD24−/CD44+‐breast CSCs significantly decreased the tumor size as compared with a low dose of doxorubicin alone that was comparable to the high dose of doxorubicin treated group suggesting the enhanced therapeutic potential of EGFR inhibitor in reducing doxorubicin‐mediated breast tumor growth. This evidence concerns the gene EGFR and neoplasm.